Dissemination of ISAR BACS

Precision or country and post-code medicine? 

This study showed a high degree of variability in ease of access to severe asthma biologics across countries. In fact, the vast majority of countries surveyed had more stringent access criteria than those stipulated by EMA! Our newly developed biologic accessibility score (BACS) allows you to see at a glance how easy or difficult it is to access biologics in your country. Check out this figure to see how you compare to other countries for access to benralizumab. 

For more details, you can access the full article here: https://lnkd.in/gZBJPiqE
Download a summary slide set: https://lnkd.in/gTFUTqky
Link to ISAR research summary slide set: https://lnkd.in/gC9j2phA

#ISAR #Severeasthma #Biologicaccessibility #Biologiceligibility #personalisedmedicine

Biologic accessibility scores for benralizumab around the world.
No alternative text description for this image